Report: Walmart opens second retail clinic with St. Mary’s Medical Group
RENO, Nevada — St. Mary’s Medical Group once again is teaming up with Walmart to open up a second retail-based health clinic in Nevada, according to local news reports.
According to reports, the second location is opening on Tuesday at the Walmart store on Kietzke Lane.
Dan Ferguson, chief medical officer for St. Mary’s Medical Group, was quoted as saying, "Retail clinics are becoming a growing trend in Nevada, which is why we moved ahead with opening a second clinic in northern Nevada. The new retail model allows patients to access basic healthcare services in a setting that’s convenient for them."
The first location opened in October 2010 at the Spanish Springs Walmart store.
Report: Rxs for Viagra, Cialis get boost from Valentine’s Day
NEW YORK — It shouldn’t surprise people too much, but pills to treat male impotence tend to see big increases in prescriptions around Valentine’s Day, according to published reports.
Bloomberg reported that prescriptions of such drugs as Pfizer’s Viagra (sildenafil) and Eli Lilly’s Cialis (tadalafil) are at their highest in the days leading up to the holiday.
According to Pfizer financial data, U.S. sales of Viagra were $253 million in first quarter 2010, compared with $234 million in the second quarter and $242 million in the third quarter, though the fourth quarter also saw a large increase in sales to $263 million.
Mylan gets approval for generic version of Vfend
PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday.
Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the 50-mg and 200-mg strengths. The drug is a triazole antifungal agent.
The tablets are a generic version of Pfizer’s Vfend, which had sales of $186 million in 2010, according to IMS Health. Mylan launched its version of the drug under a settlement with Pfizer.
Mylan was the first company successfully to file with the Food and Drug Administration for approval of generic voriconazole tablets and to include in its application a Paragraph IV certification — a legal assertion that the patents covering Vfend are invalid, unenforceable or won’t be infringed — thus entitling it to 180 days of market exclusivity in which to compete directly with the branded version.